NCT01585194View on ClinicalTrials.gov

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

November 29, 2012

Primary Completion Date

December 2, 2019

Study Completion Date

May 14, 2024

Conditions
Metastatic Uveal MelanomaStage IV Uveal Melanoma AJCC v7
Interventions
BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01585194 - Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | Biotech Hunter | Biotech Hunter